Physician profile
Ruby Patel
NPI 1457130882
$5,060.31
in general payments reported to CMS, 2019-2025
21 companies · $4,944 in 2025
The $4,944 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $116 · 2025: $4,944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,174 · Travel and Lodging: $725 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,173.53 |
| Travel and Lodging | $724.87 |
| Education | $161.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,174.67 | 2025 | Minimed 780g, Intellis Adaptivestim |
| Novo Nordisk INC | $650.32 | 2025 | Ozempic, Wegovy, Rybelsus |
| Beta Bionics, INC. | $467.35 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Cequr Corporation | $429.64 | 2025 | Cequr Simplicity |
| Abbott Laboratories | $386.96 | 2025 | Freestyle Libre 3 |
| Insulet Corporation | $355.89 | 2025 | Omnipod, Omnipod |
| Lilly USA, LLC | $291.78 | 2025 | Zepbound, Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.33 | 2025 | Jardiance |
| Galvanize Therapeutics, INC | $151.30 | 2025 | Aliya System |
| Amgen INC. | $139.76 | 2025 | Evenity |
| Noah Medical Corporation | $123.68 | 2025 | Galaxy |
| Neurelis, INC. | $116.16 | 2024 | Valtoco |
| Tandem Diabetes Care, INC. | $111.36 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Rgh Enterprises LLC | $109.07 | 2025 | |
| Dexcom, INC. | $99.54 | 2025 | Dexcom G6 Transmitter |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $82.63 | 2025 | Twiist |
| Xeris Pharmaceuticals, INC. | $72.92 | 2025 | Gvoke Hypopen, Recorlev |
| Corcept Therapeutics | $38.62 | 2025 | Korlym |
| Madrigal Pharmaceuticals | $33.94 | 2025 | Rezdiffra |
| Abbvie INC. | $31.81 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.58 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruby Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.